320 related articles for article (PubMed ID: 30859384)
1. Lipoprotein(a)-antisense therapy.
Vogt A
Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):51-56. PubMed ID: 30859384
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Viney NJ; van Capelleveen JC; Geary RS; Xia S; Tami JA; Yu RZ; Marcovina SM; Hughes SG; Graham MJ; Crooke RM; Crooke ST; Witztum JL; Stroes ES; Tsimikas S
Lancet; 2016 Nov; 388(10057):2239-2253. PubMed ID: 27665230
[TBL] [Abstract][Full Text] [Related]
3. Lipoprotein(a)-apheresis in the light of new drug developments.
Vogt A
Atheroscler Suppl; 2017 Nov; 30():38-43. PubMed ID: 29096859
[TBL] [Abstract][Full Text] [Related]
4. Hyperlipoproteinaemia(a) - apheresis and emerging therapies.
Vogt A
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):12-17. PubMed ID: 28185213
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein(a) Antisense Oligonucleotides: A New Treatment Option for Lowering Elevated Lipoprotein(a)?
Schreml J; Gouni-Berthold I
Curr Pharm Des; 2017; 23(10):1562-1570. PubMed ID: 28128058
[TBL] [Abstract][Full Text] [Related]
6. Latest developments in the treatment of lipoprotein (a).
Bos S; Yayha R; van Lennep JE
Curr Opin Lipidol; 2014 Dec; 25(6):452-60. PubMed ID: 25318824
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives.
Wu MF; Xu KZ; Guo YG; Yu J; Wu Y; Lin LM
Cardiovasc Drugs Ther; 2019 Dec; 33(6):739-748. PubMed ID: 31655942
[TBL] [Abstract][Full Text] [Related]
8. Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)
Marcovina SM; Viney NJ; Hughes SG; Xia S; Witztum JL; Tsimikas S
J Clin Lipidol; 2018; 12(1):122-129.e2. PubMed ID: 29174389
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.
Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Hohenstein B; Roeseler E; Heigl F; Grützmacher P; Blume H; Klingel R; Vogt A;
Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):33-38. PubMed ID: 30838552
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein(a) Management: Pharmacological and Apheretic Treatment.
Hanssen R; Gouni-Berthold I
Curr Med Chem; 2017; 24(10):957-968. PubMed ID: 28078998
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein(a): the revenant.
Gencer B; Kronenberg F; Stroes ES; Mach F
Eur Heart J; 2017 May; 38(20):1553-1560. PubMed ID: 28329241
[TBL] [Abstract][Full Text] [Related]
12. Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice.
Stulnig TM; Morozzi C; Reindl-Schwaighofer R; Stefanutti C
Curr Atheroscler Rep; 2019 Jul; 21(10):37. PubMed ID: 31350625
[TBL] [Abstract][Full Text] [Related]
13. Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
Waldmann E; Vogt A; Crispin A; Altenhofer J; Riks I; Parhofer KG
Atherosclerosis; 2017 Apr; 259():20-25. PubMed ID: 28279833
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein(a) - Marker for cardiovascular risk and target for lipoprotein apheresis.
Klingel R; Heigl F; Schettler V; Roeseler E; Grützmacher P; Hohenstein B; Vogt A; Fassbender C; Heibges A; Julius U
Atheroscler Suppl; 2019 Dec; 40():17-22. PubMed ID: 31818445
[TBL] [Abstract][Full Text] [Related]
15. Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.
Boffa MB
Curr Atheroscler Rep; 2016 Dec; 18(12):69. PubMed ID: 27761705
[TBL] [Abstract][Full Text] [Related]
16. Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.
Viney NJ; Yeang C; Yang X; Xia S; Witztum JL; Tsimikas S
J Clin Lipidol; 2018; 12(3):702-710. PubMed ID: 29574075
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein(a)--An independent causal risk factor for cardiovascular disease and current therapeutic options.
Kassner U; Schlabs T; Rosada A; Steinhagen-Thiessen E
Atheroscler Suppl; 2015 May; 18():263-7. PubMed ID: 25936335
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
Klingel R; Heibges A; Fassbender C
Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
[TBL] [Abstract][Full Text] [Related]
19. Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on.
Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Grützmacher P; Blume H;
Atheroscler Suppl; 2017 Nov; 30():50-55. PubMed ID: 29096861
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease.
Moriarty PM; Gray JV; Gorby LK
J Clin Lipidol; 2019; 13(6):894-900. PubMed ID: 31753721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
